Carbamazepine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Protected "Carbamazepine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Changed protection level for "Carbamazepine" ([Edit=Allow only autoconfirmed users] (expires 19:13, 26 February 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 19:13, 26 February 2014 (UTC))))
(No difference)

Revision as of 19:13, 12 February 2014

Carbamazepine
File:Carbamazepine.png
File:Carbamazepine 3D.png
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability80%
Protein binding76%
MetabolismHepatic—by CYP3A4, to active epoxide form (carbamazepine-10,11 epoxide)
Elimination half-life25–65 hours
Excretion2–3% excreted unchanged in urine
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H12N2O
Molar mass236.269 g/mol

Carbamazepine ("CBZ") is an anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy and bipolar disorder. It is also used to treat ADD, ADHD, schizophrenia and trigeminal neuralgia.

Trade names

Carbamazepine has been sold under the names Tegretol, Biston, Calepsin, Carbatrol, Epitol, Equetro, Finlepsin, Sirtal, Stazepine, Telesmin, Timonil, Trimonil, Epimaz, and Degranol (in South Africa)[1].

History

Carbamazepine was discovered by chemist Walter Schindler at J.R. Geigy AG (now part of Novartis) in Basel, Switzerland, in 1953.[2] Schindler then synthesized the drug in 1960, before its anti-epileptic properties had been discovered.

Carbamazepine was first marketed as a drug to treat trigeminal neuralgia in 1962. It has been used as an anticonvulsant in the UK since 1965, but only approved in the U.S. since 1974.

Adverse effects

Carbamazepine renders certain methods of hormonal contraception ineffective because it is an enzyme inducer of the cytochrome P450 system which metabolises the oral contraceptive, leaving less active contraceptive in the plasma.

Common side effects include drowsiness, motor coordination impairment and/or upset stomach. Carbamazepine preparations can greatly decrease alcohol tolerance.

Less common side effects include cardiac arrhythmias, blurry or double vision and/or the temporary or mild loss of blood cells or platelets. In rare cases the latter can be life-threatening if unnoticed, so frequent blood tests are required during the first few months' use, followed by three or four tests per year. In the UK testing would be less frequent in long-term use, typically once every year or two. Underactivity of the thyroid gland may be provoked, so thyroid function tests are advisable every year or two.

Small reductions in white cell count and serum sodium are common.

There are also reports of an auditory side effect, whereby patients perceive musical notes about a semitone lower than their actual pitch (so middle C would be heard as the note B3 just below it, etc).

Oxcarbazepine, a derivative of carbamazepine, has fewer and less serious side effects.

Carbamazepine may cause SIADH (syndrome of inappropriate antidiuretic hormone), since it both increases the release and potentiates the action of ADH (vasopressin).

Carbamazepine may aggravate juvenile myoclonic epilepsy, so it is important to mention any history of jerking, especially in the morning, before starting to take this drug.

Pregnant women taking carbamazepine for seizures are putting their fetuses at increased risk for teratogenic effects and should be given folic acid supplementation and undergo prenatal ultrasonography for diagnosis.

In addition, carbamazepine has been linked to serious adverse cognitive effects, including EEG slowing[3] and cell apoptosis[4].

Mechanisms

The mechanism of action of carbamazepine and its derivatives is relatively well understood. Voltage-gated sodium channels are the molecular pores that allow brain cells (neurons) to generate action potentials, the electrical events that allow neurons to communicate over long distances. After the sodium channels open, to start the action potential, they inactivate, essentially closing the channel. Carbamazepine stabilizes the inactivated state of sodium channels, meaning that fewer of these channels are available to open, making brain cells less excitable.

Interactions

Valproic acid and valnoctamide both interact with carbamazepine, as they inhibit microsomal epoxide hydrolase (mEH), the enzyme responsible for the breakdown of carbamazepine-10,11 epoxide into inactive metabolites.[5] By inhibiting mEH, valproic acid and valnoctamide cause a buildup of the active metabolite, prolonging the effects of carbamazepine and delaying its excretion.

Carbamazepine,as CYP 450 inducer, may increase clearance of many drugs, decreasing their blood levels.

See also

Notes

  1. ↑ http://www.intekom.com/pharm/lennon/degranol.html
  2. ↑ Schindler W, Häfliger F (1954). "Über Derivate des Iminodibenzyls". Helvetica Chimica Acta 37 (2): 472–483. doi:10.1002/hlca.19540370211.
  3. ↑ http://www.blackwell-synergy.com/doi/abs/10.1046/j.1528-1157.2002.22501.x
  4. ↑ http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=8719616&dopt=AbstractPlus
  5. ↑ Gonzalez, Frank J. (2006). "Drug Metabolism". In Laurence Brunton, John Lazo, Keith Parker (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th ed. ed.). New York: McGraw-Hill. pp. p. 79. ISBN 978-0071422802. Unknown parameter |coauthors= ignored (help)

External links

Template:Anticonvulsants


de:Carbamazepin fa:کاربامازپین hr:Karbamazepin it:Carbamazepina hu:Karbamazepin nl:Carbamazepine sv:Karbamazepin

Retrieved from "https://www.wikidoc.org/index.php?title=Carbamazepine&oldid=942781"